RPL17 and lung cancer: Immunotherapy has become the centre stage in the field of second-line treatment of cancer treatment, and anti-PD-1 therapy has shown objective responses in a variety of human malignancies, including lung cancer, melanoma, and bladder cancer [25, 26].